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Introduction
Uncontrolled hypertension (HTN) is a major risk factor 
associated with myocardial infarction, stroke, renal failure, 
and death.1 Numerous well-controlled trials describe the 
effectiveness and efficacy of medication therapy to curtail 
these risks.2-4 Race, specifically being of African American 
ancestry, remains a risk factor for uncontrolled HTN and 
poorer cardiovascular disease outcomes.5 There is substan-
tial interest in eliminating this inequity, including support 
for implementing multilevel approaches that simultane-
ously address multiple levels of the socioecological model 
to address this complex condition.6 These strategies include 
practice-level interventions, such as practice facilitation, 
decision support, and treatment intensification, as well as 
patient and community level interventions, such as home 
blood pressure (BP) monitoring and health coaching.6-8 
Prior evidence suggests value in guiding providers to more 
readily intensify medication therapies, avoiding challenges 
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Abstract
Background: Racial disparities in blood pressure (BP) control persist, but whether differences by race in antihypertensive 
medication intensification (AMI) contribute is unknown. Objective: To compare AMI by race for patients with elevated 
home BP readings. Methods: This prospective cohort study followed adult patients from 6 rural primary care practices who 
used home BP monitoring (HBPM) and recorded/reported values. For providers, AMI was encouraged when mean HBPM 
systolic blood pressure (SBP) values were ⩾135 mm Hg; patients received phone-based coaching on HBPM technique and 
sharing HBPM findings. AMI was assessed between baseline and 12 months using defined daily dose (DDD) and summed to 
create a total antihypertensive DDD value. Results: A total of 217 patients (mean age = 61.4 ± 10.2 years; 66% female; 57% 
black) provided usable HBPM data. Among 90 (41%) intensification-eligible hypertensive patients (ie, mean HBPM SBP values 
for 6-months ⩾135 mm Hg), mean total antihypertensive DDD was increased in 61% at 12 months. Blacks had significantly 
higher mean DDD at baseline and 12 months, but intensification (+0.72 vs +0.65; P = 0.83) was similar by race. However, 
intensification was greater in males than females (+1.1 vs +0.39; P = 0.031). Reduction in mean SBP following intensification 
was greater in white versus black patients (−8.2 vs −3.9 mm Hg; P = 0.14). Conclusion/Relevance: Treatment intensification 
in HBPM users was similar by race, differed significantly by gender, and may produce a greater response in white patients. 
Differential AMI in HBPM users does not appear to contribute to persistent racial disparities in BP control.
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of clinical inertia that can unnecessarily prolong states of 
uncontrolled HTN. How to best measure intensification is 
unknown.9-11 Most prior methods of measuring treatment 
intensification model these changes based on point-of-care 
measurements but provide limited information on the spe-
cific medication changes that were made. Furthermore, 
there is little published on patterns of medication intensifi-
cation when home BP monitoring (HBPM) data are used to 
evaluate medication intensification.
The Heart Healthy Lenoir project was a community-
based participatory research model involving multilevel 
quality improvement efforts to reduce racial disparities in 
BP control in rural primary care practices; the methods have 
been previously described in detail.8 Briefly, the study 
included a formative phase, where we collected qualitative 
data from patients, providers, and office staff on the 
resources and barriers affecting BP control in their region, 
followed by an implementation phase. During the imple-
mentation phase, we conducted a practice-based interven-
tion using a quality improvement approach, with strategies 
designed to change practice (via practice-facilitator led 
sequential plan-do-study-act cycles with practice staff) and 
patient (via a trained, health coach–led protocol of tele-
phone-based emotional support and coaching for patients) 
behavior. The theory-driven intervention was designed to 
improve BP control and reduce disparities in the targeted 
community, while having a limited impact on office-based 
patient flow. The study was approved by the Institutional 
Review Board at the University of North Carolina—Chapel 
Hill, and each patient provided written informed consent. 
BP control in a cohort of patients from these practices 
improved from baseline to 12-month follow-up in both 
black and white patients. Specifically, both black (−5.0 mm 
Hg) and white (−7.8 mm Hg) patients had a significant 
decrease in mean systolic blood pressure (SBP); however, 
the between-racial group differences were not statistically 
significant.12 The purpose of the present study was to evalu-
ate whether differential patterns of treatment intensification 
occurred between black and white patients in the Heart 
Healthy Lenoir study and to explore the use of the defined 
daily dose (DDD) as a methodology for defining medica-
tion treatment intensification in patients using HBPM.
Methods
Overall Study
The present data come from patients in the Heart Healthy 
Lenoir study, described in detail previously.8,12-14 Briefly, 
the study was a prospective cohort study of HTN control 
involving multilevel quality improvement in 6 rural pri-
mary care practices in an economically distressed county in 
the southeastern United States. A nonrandomized observa-
tional trial design was selected to maximize feasibility and 
acceptability for conducting this research in busy rural pri-
mary care practices unaccustomed to participating in 
research and to facilitate broad community participation, 
important to addressing health disparities. A sample of 
black and white patients (race was self-identified) from 
each of the 6 small- (1-3 providers) to medium-sized (4-10 
providers) practices represented the impact of the system-
level (quality improvement training) and patient-level 
(health coaching) intervention components. A total of n 
=525 adult patients being seen in 1 of the 6 rural primary 
care practices with an established HTN diagnosis and at 
least 1 visit in the past year with an uncontrolled SBP mea-
surement (SBP ⩾ 150 mm Hg) based on office BP readings 
participated in the Heart Healthy Lenoir study. Patient data 
for this study were collected at enrollment and at the 6- and 
12-month follow-up visits at a research center.
Each participant was given an oscillometric home BP
monitor (Omron BP 785 or Omron BP 652) and was taught 
accurate measurement techniques at his or her baseline 
visit. Patients were instructed to measure and record their 
BP 3 times per week with some measurements reflecting 
both am and pm values. Participants kept logs of their mea-
surements and were asked to bring their logs to their office 
visits and to have them on hand during their 12 monthly 
phone coaching calls for review by their health coach. Via 
practice facilitation efforts, primary care providers and staff 
from the 6 practices were trained in the use of HBPM and 
how to use these data in clinical decision making.
Sample for the Present Study
In the present study, the investigators focused only on eli-
gible patients from the Heart Healthy Lenoir study who 
used HBPM and who provided data at follow-up research 
clinic visits from at least 12 home BP measurements in each 
of two 6-month periods: the initial 6 months following 
enrollment up to the 6-month research clinic visit and the 
subsequent period between the 6-month and 12-month fol-
low-up visits at the research clinic. A total of 12 measure-
ments were considered to be the minimum number of 
HBPM readings necessary to consider the patient as having 
adopted HBPM monitoring and to characterize mean SBP, 
based on the guidelines published by Pickering et al.15 
Those patients with a mean SBP from HBPM in the initial 6 
months following enrollment of ⩾135 mm Hg were defined 
as being eligible for treatment intensification based on prior 
published guidelines.15
At baseline and at the 6- and 12-month follow-up 
research clinic visits, patients brought their prescription 
and over-the-counter medications to their study visits 
where research assistants collected the medication data. 
Antihypertensive medication treatment intensity for each 
person was quantified using a DDD approach. This method 
was developed for pharmacoepidemiological research by 
the World Health Organization16 (WHO) Collaborating 
Centre for Drug Statistics Methodology and has been used 
in other studies to estimate the intensity of medication use 
for various disease states.17,18 The DDD is the assumed 
average maintenance dose per day for a drug used for its 
main indication in adults; this dose is assigned a value of 1. 
Therefore, patients taking half of the usual daily dose are 
assigned a value of 0.5 for that medication, whereas 
patients taking twice the usual daily dosage (as a single 
dose or in divided daily doses) would be assigned a value 
of 2 for that specific medication. For this study, the total 
antihypertensive DDD was computed as follows. Each 
patient’s antihypertensive medications were identified 
from their list of medications at baseline, 6-month, and 
12-month follow-up visits, and the individual DDD for
each individual antihypertensive medication was deter-
mined by using the WHO online library of individual DDD
values for all medications (http://www.whocc.no/atc_ddd
_index/). The total antihypertensive medication intensity
for each patient at each time point was then computed as
the sum of all individual antihypertensive medication DDD
values (ie, the sum of the DDDs for each antihypertensive
medication). The change in antihypertensive medication
treatment intensity (ie, change in total antihypertensive
medication DDD) was then computed from baseline to the
12-month follow-up visit. Data from the 12-month follow-
up visit were specifically chosen because this was the
period of maximal training for patients by health coaches
regarding HBPM. Medication adherence was assessed at
baseline using a 4-item validated scale.19
Patient population characteristics were analyzed using 
descriptive statistics, including means (±SD) and propor-
tions. Baseline characteristics were compared between 
study groups as follows: means for continuous measures 
such as age, BP, and body mass index (BMI) were com-
pared using independent-samples t-tests, whereas propor-
tions (eg, female sex, low household income, presence of 
diabetes) were compared using the χ2 test. Significance 
level for all comparisons was set at P ⩽0.05. Changes in 
mean antihypertensive DDD values were compared from 
baseline to 12-month follow-up in all participants and by 
race groups (black vs white) using independent-samples 
t-tests, whereas proportions of patients taking various anti-
hypertensive classes were compared using the χ2 test, to
define overall and race-specific patterns of treatment inten-
sification. Changes in mean anti-hypertensive DDD and
changes in the mean number of anti-hypertensive classes
being taken were examined by Pearson correlation. Changes 
in mean SBP were also evaluated in those in whom treat-
ment was intensified (ie, increase in DDD from baseline to
12-month follow-up) and these changes compared by race
using independent samples t-test. A limited multivariate
analysis using linear modeling was completed to examine
potential correlates of mean DDD at baseline and again at
the 12-month follow-up. This analysis included age, race,
sex, and health insurance status (insured vs uninsured) as
potential covariates of interest.
Results
Of the 509 patients in the Heart Healthy Lenoir study with 
complete medication data, a total of 217 (42.6%) reported 
regularly using HBPM and provided 12 or more home BP 
readings during each of two 6-month periods. The mean 
number of home BP readings reported during both the two 
6-month time periods were not significantly different by
race (initial 6 months: black = 77 ± 51 vs white = 68 ± 53
readings [P = 0.27]; second 6 months: black = 70 ± 63 vs
white = 60 ± 52 readings [P = 0.22]). Of the 217 with
available HBPM data, 90 patients (41%; n = 55 black, n =
35 white) were identified as “eligible” for treatment intensi-
fication based on having a mean HBPM SBP ⩾135 mm Hg
during the initial 6-month period. The characteristics for
these patients are given in Table 1. Black patients reported
Table 1. Baseline Characteristics of Patients with a Mean HBPM Systolic BP ⩾135 mm Hg During the Initial 6-Month Period.
Overall, n = 90 Black, n = 55 White, n = 35 P Value
Demographics
Age, mean (±SD) 64 (±11) 64 (±12) 64 (±9) 0.78
Female sex (%) 57% 58% 54% 0.82
 Education: ⩽high school (%) 76% 85% 63% 0.02
Household income ⩽$40 000 (%) 85% 98% 68% 0.001
CVD and risk factors for CVD
Diabetes, n (%) 42 (47%) 31 (60%) 11 (32%) 0.02
Mean systolic BP (±SD) mm Hg 148.6 (20.9) 148.6 (22.0) 148.7 (19.2) 0.98
Mean diastolic BP (±SD) mm Hg 81.9 (13.1) 81.9 (14.7) 82.0 (10.3) 0.97
Low medication adherence, n (%) 29 (34%) 20 (38%) 9 (29%) 0.48
Body mass index (±SD) 35.2 (8.5) 36.3 (8.9) 33.4 (7.4) 0.12
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; HBPM, home BP monitoring.
significantly lower household income and educational level 
as well as a greater prevalence of diabetes. Low medication 
adherence was reported more commonly, and BMI was 
modestly greater among black patients, but neither differ-
ence was statistically significant. There were modest differ-
ences in the number of antihypertensives by race, with 
black patients taking more antihypertensive medications 
than white patients. Likewise, there were differences in pre-
scribing by therapeutic class, with a higher percentage of 
blacks taking diuretics and calcium channel blockers (see 
Table 2).
Figure 1 shows the change in treatment intensity (mean 
total antihypertensive DDD) in this subgroup by race at 
both baseline and at 12-month follow-up. Black patients 
had significantly higher mean total antihypertensive DDD 
values at both baseline (3.34 vs 1.99; P = 0.015) and at 
12-month follow-up (4.02 vs 2.80; P = 0.027). Multivariate
linear modeling that examined age, race, sex, and health
insurance status as potential correlates of mean DDD at
both baseline and 12-month follow-up time points demon-
strated similar relationships, and notably that race was the 
only significant independent correlate at both time points 
(see Table 3). However, the change in mean total antihyper-
tensive DDD from baseline to 12-month follow-up was not 
statistically significantly different by race (see Figure 1; 
+0.72 vs +0.65, P = 0.83). The proportion of black
patients with any increase in mean total antihypertensive
DDD was slightly higher than in white patients (66.7% vs
56.3%, respectively), but this difference was not statisti-
cally significant. However, there was a modest but signifi-
cantly greater change in mean total antihypertensive DDD
from baseline to 12-month follow-up by gender, with male
patients having more treatment intensification (+1.1 ± 1.4
in males vs +0.40 ± 1.5 in female patients; P = 0.03).
Only 12 (21%) black patients versus 4 (11%) white patients
(P = 0.27) had any decrease in mean total antihypertensive
DDD or de-escalation of treatment from baseline to
12-month follow-up.
Table 2. Baseline Use of Antihypertensives, by Class With Overall AH DDD.
Overall, n = 90 Black, n = 55 White, n = 35 P Value
AH DDD and count of AH medications
Mean AH DDD (SD) 2.8 (2.6) 3.3 (2.7) 2.0 (2.1) 0.01
 AH medication count, mean (SD) 2.0 (1.3) 2.2 (1.3) 1.7 (1.3) 0.09
Percentage of patients on each drug class
 Diuretics 39% 47% 26% 0.05
ACE inhibitors 45% 49% 40% 0.51
 ARBs 17% 17% 17% 1.0
 Ca++ channel blockers 32% 40% 20% 0.06
β-Blockers 41% 38% 46% 0.51
Abbreviations: ACE, angiotensin-converting enzyme; AH, antihypertensive; ARB, angiotensin receptor blocker; DDD, defined daily dose.
Figure 1. Change in mean (±standard error) total antihypertensive defined daily dose (DDD) values by race from baseline to 
12-month follow-up in all patients (n = 90) with initial 6-month period mean home-measured systolic blood pressure readings ⩾135
mm Hg.
In the entire sample (n = 90), the mean increase at 12 
months in number of antihypertensive medication classes 
(+0.4 ± 0.9 in white patients vs +0.3 ± 1.0 in black 
patients; P = 0.60) was not significantly different by race. 
Table 4 shows antihypertensive medication classes by race 
at baseline and 12-month follow-up in the subset of patients 
(n = 52) who received treatment intensification (ie, higher 
total antihypertensive DDD at 12-month follow-up). These 
data suggest modest increases in multiple medication 
classes (angiotensin-converting enzyme [ACE] inhibitor, 
diuretic, calcium channel blocker, etc) as part of intensifica-
tion, without a significant difference by race. Furthermore, 
there was a significant positive correlation between the 
change in DDD and the change in the mean number of anti-
hypertensive medication classes that were reported being 
used from baseline to 12-month follow-up (Pearson correla-
tion = 0.37; P = 0.001).
Among the 90 patients eligible for intensification, the 
mean change in SBP at 12-month follow-up was greater in 
those with an increase in antihypertensive treatment (ie, 
DDD increased; n = 52) compared with those who had no 
change or a lower antihypertensive treatment intensity 
(DDD same or lower, n = 38; −5.2 ± 9.4 vs −2.6 ± 12.4 
mm Hg; P = 0.30), although this did not achieve statistical 
significance. In this group, the decline in SBP among those 
with an increase in DDD was greater, although nonsignifi-
cantly, in white patients than in black patients (−8.2 ± 9.1 
vs −3.9 ± 9.4; P = 0.14) despite relatively comparable 
changes across races in mean DDD (+0.72 vs +0.65; P = 
0.83). Furthermore, 73% (n = 38/52) of those with an 
increase in mean DDD had some degree of decline in SBP 
between baseline and 12-month follow-up. With respect to 
goal BP achievement, 54% (n = 19) of white patients ver-
sus 44% (n = 24) of black patients achieved target BP val-
ues (<140/90 mm Hg) at the 12-month follow-up research 
visit (P = 0.50). Specifically, the percentage of patients 
meeting target BP values increased in both race groups from 
baseline to 12-month follow-up (white patients increasing 
from 34% to 54%; black patients increasing from 33% to 
44%). The proportion of patients reporting low medication 
adherence was unchanged from baseline (35%) to 12-month 
follow-up (36%), with no significant differences by race at 
either time point.
Discussion
Differences in HTN control by race persist and may be asso-
ciated with disparate cardiovascular outcomes. When BP 
Table 3. Comparison of 2 Multivariate Linear Models Examining Potential Correlates of Mean Total Antihypertensive DDD as the 
Outcome of Interest.a
Potential Correlate Standardized β (95% CI) P Value
Mean total antihypertensive DDD at baseline as outcome
Sex (M/F) −0.043 (−1.3 to 0.85) 0.68
Age (years) −0.17 (−0.096 to 0.013) 0.14
Race (black vs white) 0.27 (0.31 to 2.5) 0.01
Health insurance (yes or no) 0.22 (−0.05 to 2.6) 0.06
Mean total antihypertensive DDD at 12-month follow-up as outcome
Sex (M/F) −0.13 (−1.7 to 0.41) 0.22
Age (years) −0.08 (−0.07 to 0.04) 0.48
Race (black vs white) 0.25 (0.18 to 2.3) 0.02
Health insurance (yes or no) 0.73 (−0.90 to 1.7) 0.53
Abbreviations: DDD, defined daily dose; F, female; M, male.
aFirst at baseline only and second at 12-month follow-up only.
Table 4. Change in Percentage of Patients (PTS) Receiving Various Antihypertensive Medication Classes in the Subset of Patients 
With Home BP Monitoring Data Who Were Eligible for and Received Treatment Intensification, by Race (n = 52).
Antihypertensive Class
Baseline in White 
PTS (n = 18)
12-Month Follow-up
in White PTS
Baseline in Black 
PTS (n = 34)
12-Month Follow-up
in Black PTS
P Value for 
Difference by Race
ACE inhibitor 33% 50% 41% 53% 1.0
Angiotensin receptor blocker 16% 16% 17% 23% 0.54
β-Blocker 39% 61% 35% 41% 0.43
Diuretic 11% 39% 35% 59% 1.0
Calcium channel blocker 22% 44% 38% 50% 0.7
Abbreviations: ACE, angiotensin-converting enzyme; BP, blood pressure.
control is determined to be inadequate during office-based 
visits, providers may have questions or concerns related to 
medication adherence, adverse effects, affordability, and so 
on. Regardless of these potential causes of elevated office 
BP readings, antihypertensive therapy is often intensified 
during that office visit. In addition, HBPM is often recom-
mended as an important strategy in HTN management 
because of its improved consistency with 24-hour ambula-
tory BP measures, improved reproducibility, and better cor-
relation with target organ damage and because it helps 
overcome the challenges associated with using only office-
based measurement.15 However, it is unclear the extent to 
which HBPM use and the associated encouragement of 
patients to share HBPM readings with their provider influ-
ences treatment intensification and whether differential pat-
terns of treatment intensification may occur by race in this 
situation, particularly in rural primary care settings. The 
present study is unique in that it examines treatment intensi-
fication patterns by race in rural primary care patients who 
use HBPM and who have been specifically encouraged to 
share those readings with their providers.
Furthermore, the present study uses an innovative 
numerical measure of antihypertensive treatment intensity 
(total antihypertensive DDD) that has only been tried in 1 
prior study,20 which was outside the United States. This 
metric allows more careful examination of both total anti-
hypertensive medication use as well as which medication 
classes are used/changed in treatment intensification efforts. 
This use of the DDD measure for antihypertensive medica-
tions was initially used by McManus et al20 in their trial of 
HBPM and antihypertensive self-titration by hypertensive 
patients in the United Kingdom. The present findings dem-
onstrate the utility of the total antihypertensive DDD for 
characterizing the intensity of antihypertensive treatment 
and its changes across a 1-year follow-up period. There was 
a good correlation between increasing DDD values and 
increases in the mean number of antihypertensive medica-
tion classes used. Although the mean number of antihyper-
tensive medications is useful, the value of the DDD is that 
it also allows for measuring treatment intensification asso-
ciated with dosage increases for antihypertensive medica-
tions. The total antihypertensive DDD consolidates 
information from the number of medications, classes of 
medications, and dosage into a single numerical measure 
that can be tracked over time. The DDD can also be used to 
characterize treatment intensity with individual therapeutic 
classes of antihypertensive medications, providing insight 
into the race-specific or other subgroup prescribing of vari-
ous classes as shown in this study.
In this study, black patients reported taking more antihy-
pertensive medications at both time points, but changes in 
the pattern of use of various antihypertensive medication 
classes in the subset of patients in whom intensification 
occurred was not significantly different by race. ACE 
inhibitor and ARB use increased in both racial groups, 
whereas diuretic and calcium channel blocker use remained 
higher in black patients at both time points. This pattern of 
greater prescribing of diuretics and calcium channel block-
ers in black patients is consistent with the recommendations 
of the committee originally empaneled for JNC 8.1 Also, 
β-blockers were utilized more frequently than anticipated, 
especially for intensification in white patients, although the 
extent to which other indications for β-blocker use were 
present is not clear.
Mean SBP was slightly higher among black patients at 
baseline, even though they were younger, but this differ-
ence was not statistically significant. Antihypertensive 
medication intensity was higher at baseline and at 12-month 
follow-up among black patients, but the magnitude of treat-
ment intensification (mean change in total antihypertensive 
DDD) was not different by race. This suggests that rural
primary care providers intensify medication therapy for
patients with a history of uncontrolled HTN, regardless of
race. This finding is consistent with that reported by Blair
et al21 who showed that clinician’s level of implicit bias did
not influence treatment intensification for HTN for African
American patients in routine office care in an urban setting.
The present study extends these findings and demonstrates
a similar lack of bias in treatment intensification in rural
practice in patients who were encouraged to share HBPM
data with their provider.
Intensification of treatment led to a reduction of SBP in 
most patients, and this is consistent with the findings of 
Daugherty et al,22 who demonstrated that intensification 
was more likely to result in improved BP control. As a 
result, however, among those who received treatment inten-
sification, reduction in SBP was modestly greater in white 
than in black patients. Furthermore, our findings showed 
that, despite intensification similarities, a smaller percent-
age of black patients achieved targeted BP values. The find-
ings in this study are consistent with those reported by Cené 
et al,12 who demonstrated that 62% of white patients versus 
52% of black patients with uncontrolled BP at baseline 
achieved targeted BP values at 12-month follow-up. These 
results are similar to previous reports demonstrating some 
racial differences in the magnitude of response to various 
antihypertensive agents.23,24 It remains unclear whether spe-
cific pharmacological or pharmacogenetic mechanisms 
contributed to the modestly different SBP responses 
observed by race in this subset or whether other factors such 
as lifestyle behaviors, BMI, age, and/or medication adher-
ence may have contributed. Regardless, based on the pres-
ent findings and that of others, it seems appropriate to 
support guideline25 indicated intensification of antihyper-
tensive treatment using carefully selected antihypertensive 
agents as detailed in recent guideline documents.1,25
The present study is important in that it examines spe-
cific patterns of treatment intensification by race using a 
method not previously utilized in HTN disparities research. 
However, the study also has important limitations. First, 
using a cut-point of 12 home BP measures that may have 
occurred at any time in the initial 6-month period may have 
been inadequate to accurately characterize patients as 
HBPM users and potentially in need of medication intensi-
fication. However, the patients in this study had substan-
tially more readings than 12 in both time periods (eg, mean 
= 73 in the initial time period), and the selection of 12 read-
ings as a cut-point follows the general guidelines for HBPM 
clinical decision making published by Pickering et al.15 
There are also no data to quantify the extent to which 
patients actually shared HBPM data with their providers or 
if primary care providers actually utilized HBPM results in 
evaluating and managing patients, including whether this 
specifically influenced their intensification decisions or 
office-based prescribing changes between visits. 
Furthermore, actual in-office BP measurements by the pri-
mary care provider were also not available to the investiga-
tors. The authors also acknowledge that use of the DDD 
may have limitations. For some medications, it may be dif-
ficult to determine what actually constitutes a “standard 
dose,” and the DDD score may overestimate the signifi-
cance of a dosage change compared with the addition of 
another medication. However, as noted above, this DDD 
metric may also have unique value beyond prior strategies 
to characterize intensification. Because the study had lim-
ited sample size, caution is observed in the interpretation of 
these findings, and additional research is needed to compare 
treatment intensification patterns in larger samples. No data 
were available on changes in sodium intake, changes in 
BMI, or other clinical factors that may have influenced the 
BP response between baseline and 12-month follow-up. 
Finally, this study was carried out in a rural community 
involving only black and white patients with HTN, and 
extrapolation to other racial and ethnic groups or urban 
communities may be limited.
Conclusion and Relevance
In conclusion, the present study demonstrates that rural pri-
mary care physicians intensify antihypertensive treatment 
to a similar degree in both black and white patients with 
elevated home BP readings. Furthermore, we have demon-
strated the functionality of the DDD and the total antihyper-
tensive DDD as a single metric for characterizing the extent 
to which treatment in hypertensive patients is intensified 
between 2 time points. The classes of antihypertensive 
agents used in this rural primary care cohort and in the sub-
group with treatment intensification are consistent with rec-
ommended treatment patterns. The magnitude of reduction 
in SBP following treatment intensification was greater in 
white than in black patients, but the reasons for this require 
further investigation.
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